GlassScriptPhysician profile
James W Mason
NPI 1699763375
$1,881.66
in general payments reported to CMS, 2019-2025
22 companies · $656 in 2025
The $656 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.69 · 2020: $145 · 2021: $35.36 · 2022: $199 · 2023: $337 · 2024: $460 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $482.62 | 2020-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $230.04 | 2022-2025 | |
| Leo Pharma INC. | $152.30 | 2022-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $127.08 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $120.08 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $116.34 | 2020-2024 | Blu-U, Odomzo |
| Ucb, INC. | $89.11 | 2022-2025 | Bimzelx |
| Biofrontera INC. | $87.52 | 2020-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.51 | 2024 | Spevigo, Cyltezo |
| Regeneron Healthcare Solutions, INC. | $55.32 | 2022-2025 | Dupixent |
| Abbvie INC. | $49.27 | 2019-2023 | |
| Galderma Laboratories, L.P. | $49.20 | 2021-2025 | Nemluvio |
| Incyte Corporation | $40.81 | 2025 | Opzelura |
| Janssen Biotech, INC. | $35.03 | 2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $31.35 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $26.90 | 2025 | |
| Cipher Pharmaceuticals US LLC | $20.36 | 2025 | Spinosad, Natroba |
| Dermira, INC. | $19.15 | 2020 | |
| Organon LLC | $19.08 | 2025 | Hadlima |
| Lilly USA, LLC | $16.35 | 2024 | Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.95 | 2025 | Cabtreo |
| Mylan Pharmaceuticals INC. | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.